Zolgensma and tumour reports
The FDA is investigating tumours after Zolgensma gene therapy for SMA; two are confirmed as caused by the vector inserting next to the GLI1 gene. Official sources, summary and what is unknown.
Spinal Frontiers · Safety in Focus
When a safety story spreads, the official sources, a short summary and what is still unknown, in one place for clinicians.
The FDA is investigating tumours after Zolgensma gene therapy for SMA; two are confirmed as caused by the vector inserting next to the GLI1 gene. Official sources, summary and what is unknown.
When a safety story about a medicine, device or therapy that spine teams meet starts to spread, we put the official sources in one place, with a short summary, what is still unknown and where to report. Each briefing says who it is written for.
For device recalls and safety notices, see Regulatory Watch. To report a problem, see Report a Device Problem. Corrections and suggestions: spinalfrontiers@nspine.com.
Spinal Frontiers is published by NSpine Limited, registered in England and Wales (company no. 08362634), 14 Park Row, Nottingham NG1 6GR, United Kingdom. Every item is summarised in our own words and links to its original source. Listings are a selection made at NSpine's editorial discretion and are not exhaustive; inclusion is not an endorsement, and omission implies nothing. Sponsors and advertisers have no influence on what we cover. Nothing here is medical, legal or financial advice. Spotted an error or a broken link? Email spinalfrontiers@nspine.com, or use the feedback page.
Spinal Frontiers is a trademark of NSpine GmbH.
Information only, summarised from third-party sources: not medical, legal, regulatory or financial advice. Full disclaimer.
© 2013 – 2026 NSpine Limited. Privacy notice.